In men with biochemical recurrence of prostate cancer (BCR), positron emission tomography/computed tomography (PET/CT) with radiotracers built on PSMA ligands is gaining growing use to try to localize tumor as accurately and early as possible, thereby attempting to optimize salvage therapy. This evidence concerns the gene BCR and prostate carcinoma.